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Adopting Agile Practices when developing software for use in the 
Medical Domain 
Martin McHugh*†, Fergal McCaffery and Valentine Casey 
 
Regulated Software Research Centre. Dundalk Institute of Technology, Dundalk, Co. Louth, Ireland 
SUMMARY 
Non-safety critical software developers have been reaping the benefits of adopting agile 
practices for a number of years. However, developers of safety critical software often have 
concerns about adopting agile practices. Through performing a literature review, this research 
has identified the perceived barriers to following agile practices when developing medical 
device software. A questionnaire based survey was also conducted with medical device 
software developers in Ireland to determine the barriers to adopting agile practices.  The 
survey revealed that half of the respondents develop software in accordance with a plan 
driven software development lifecycle and that they believe that there are a number of 
perceived barriers to adopting agile practices when developing regulatory compliant software 
such as: being contradictory to regulatory requirements; insufficient coverage of risk 
management activities and the lack of up-front planning. In addition, a comparison is 
performed between the perceived and actual barriers. Based upon the findings of the literature 
review and survey, it emerged that no external barriers exist to adopting agile practices when 
developing medical device software and the barriers that do exists are internal barriers such 
as getting stakeholder buy in.  
KEY WORDS: Agile Methods, Medical Device, V-Model, Plan Driven, XP, Medical Device 
Software 
1.   INTRODUCTION 
The popularity of agile practices is on the rise [1]. Agile practices appear to offer a “silver 
bullet” [2] for all of the problems associated with traditional plan driven software 
development lifecycles. A number of surveys have been completed which reinforce this 
believe [3, 4]. However, a large amount of research that has been conducted into the success 
of adopting agile practices is broad and does not expressly focus on specific domains within 
the software development industry i.e. safety critical software development.  
Non-safety critical software is developed in accordance with a customer’s requirements, 
but safety critical software must be developed in accordance with both customer requirements 
and national and/or international regulatory constraints.  These regulatory constraints are 
dictated by the region in which it is planned to market the software, be it standalone or 
embedded within a hardware device.   For example,  if a medical device is to be marketed  in 
the United States (US) it must be developed in accordance with the Food and Drug 
Administration (FDA) quality regulations, guidance documents and approved standards [5, 
6].  Software developed for use within safety critical domains is typically developed in 
accordance with the Waterfall Model or V-Model software development lifecycles [6, 7]. 
These lifecycles are defined by upfront design with high importance placed upon the 
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production of documentation [6]. These models produce the necessary deliverables required 
to achieve regulatory conformance.  
Our research is focused on the development of software for use within the medical device 
domain. Regulatory requirements and development standards such as [8, 9] do not dictate the 
use of a particular lifecycle when developing  medical device software. In fact they state that 
medical device software can be developed using a traditional, iterative and/or evolutionary 
approach. Despite this, medical device software developers typically develop software in 
accordance with the V-Model [7]. Whilst the V-Model produces necessary deliverables such 
as traceability between requirements and all stages of the software development lifecycle [10] 
it is seen as being rigid and inflexible in the event of a change once development has begun 
[11].  
This research was initiated by performing a literature review. One of the objectives of 
undertaking this literature review was the identification of the perceived barriers to adopting 
agile practices when developing medical device software. Also as part of this research a 
questionnaire based survey was conducted amongst medical device software developers in 
Ireland. The aim of this survey was to evaluate the findings of the literature review and to 
learn what the actual barriers are to adopting agile practices when developing medical device 
software. The findings of the literature review revealed that there is a slow rate of adoption of 
agile practices when developing medical device software and that there are a number of 
perceived barriers to adopting agile practices when developing medical device software [12]. 
The remainder of this paper is structured as follows: Section 2 provides information as to 
our on-going research in this area and how this aspect of our work fits into this research. In 
section 3, we outline related work which was identified through the literature review. Section 
4 details the perceived barriers to selecting and implementing agile practices when 
developing medical device software based on the results from our literature review. Section 5 
outlines the approach taken by questionnaire based survey conducted amongst medical device 
manufacturers in Ireland. Section 6 provides the results of the survey. Within section 7 a 
comparison is performed between the perceived barriers and the actual barriers to adopting 
Agile practices and finally within section 8 conclusions of this research are presented. 
2.   RESEARCH OBJECTIVES 
As part of this on-going research the following research questions have been identified: 
1. What are the issues associated with developing medical device software? 
2. What are the issues with developing medical device software using a traditional 
software development lifecycle? 
3. Can agile practices be used to develop medical device software? 
4. If agile practices can be used to develop medical device software, how must they be 
incorporated within the existing lifecycle in order to meet regulatory requirements? 
The results from the research outlined in this paper will be used to help address the third 
research question. By identifying actual barriers to the adoption of agile practices specific 
practices can be discounted and the remaining agile practices can be evaluated for suitability. 
These research questions were formed following the completion of the literature review. This 
literature review began by broadly looking at generic software development lifecycles. It 
became clear through this portion of the literature review that the generic software 
development industry is greatly benefitting from the adoption of agile software development 
methods. The focus of the literature review moved to the development of safety critical 
software and then onto the development of software in the medical device industry. 
Following this phase of the literature review, research was conducted into agile software 
development. This involved examining mainstream methodologies such as Scrum and XP. 
Once this was completed we then focused upon the adoption of agile practices in the 
development of safety critical software. Finally, we considered the adoption of agile practices 
in the development of medical device software. This literature revealed a number of 
perceived barriers to adopting agile practices when developing medical device software.  
Following the literature review a questionnaire based survey was conducted amongst 
medical device software developers in Ireland. The objective of this survey was to evaluate 
the findings of the literature review and to learn what the actual barriers to adopting agile 
practices are. 
3.   RELATED RESEARCH 
In October 2012 the Association for the AAMI released a Technical Information Report 
(TIR) known as AAMI TIR 45:2012 [13]. The committee which developed the TIR consisted 
of industry experts and FDA staff. The AAMI recognised the shift in the generic software 
development industry towards more agile practices. However, they identified that the 
available information with regard to implementing agile methods when developing medical 
device software was hard to understand and the objective of the TIR is to provide clear 
guidance on which practices of agile software development are suited to the development of 
medical device software. The TIR also provides recommendations for complying with 
international standards and FDA guidance documents when using agile practices to develop 
medical device software. 
When considering agile development methods, development organisations will 
typically look at the agile manifesto. The agile manifesto [14] contains 4 key statements and 
12 practices. The 4 key statements appear to be contradictory to the values of regulated 
software development. These 4 key statements are: 
“Individuals and Interactions over process and tools 
Working Software over comprehensive documentation 
Customer Collaboration over contract negotiation 
Responding to change over following a plan” 
However these values need not be interpreted as being contradictory to the development of 
medical device software. The AAMI TIR states; 
“they (the 4 key values) can be aligned to be complimentary, resulting in a quality 
management systems that produces high-quality medical device software” 
As discussed, medical device software developers in both the EU and the US are strongly 
recommended to follow IEC 62304 in the development of regulatory compliant software. As 
this is the case, the AAMI mapped each of the identified suitable agile practices to the 
appropriate stage of development in IEC 62304. The TIR focuses on a number of areas in 
which agile software development practices are suited when developing medical device 
software. These areas include: 
• Planning; 
• Team Structure and Collaboration; 
• Product Definition and Requirements documentation; 
• Software Architecture; 
• Detailed Design; 
• Implementation and Unit Verification; 
• Integration and Integration Testing; 
• Software System Testing; 
• Software Release; 
• Configuration Management and Change Management; 
• Corrective and Preventative Action. 
The TIR successfully maps practices performed as part of agile software development 
techniques to each of these stages of development. To accompany this TIR, a number of case 
studies have emerged from medical device software organisations which have successfully 
used agile practices within their organisation. These organisations include, Abbott 
Diagnostics [15], Medtronic [16] and Cochlear [17]. A common trend appeared in each of the 
case studies. Each organisation recognised that no single agile methodology such as Scrum or 
XP could be wholly followed in the development of medical device software. Instead, these 
organisations look at the practices contained with the individual methodologies and selected 
practices most suited to their organisational need. Additionally whilst these organisations 
selected appropriate practices to follow, for varying reasons, they choose to integrate the 
selected practices with the traditional plan driven SDLC currently in place. 
4.   PERCEIVED BARRIERS TO AGILE ADOPTION 
Software developed for use in or as a medical device must meet the regulatory requirements 
of the region where the device is being marketed. As a result many of the barriers to adopting 
agile practices, in developing medical device software are associated with regulatory controls 
[18]. The focus of this research is the identification of the perceived barriers that have a direct 
impact on the development process of medical device software and the implementation of 
agile methods in this context. Additional barriers do exist, but a number of these are 
organisational barriers that do not have a direct impact on the development of medical device 
software. An example of such an organisational barrier is that Human Resource policies and 
processes do not cater for the requirements of an Agile team [19]. The literature review   
identified the following perceived barriers to the adoption of agile practices when developing 
medical device software. 
The FDA General Principles of Software Validation (GPSV) [9] require manufacturers to 
explicitly document requirements prior to implementation and test procedures [20]. This 
would appear to be an apparent barrier to adopting agile practices as one of the fundamental 
principles of the agile Manifesto [21] is “working software over comprehensive 
documentation”. Combined with this, another central principle of agile software development 
is that requirements are fluid and changes in requirements can be easily accommodated and 
are even welcomed throughout a development project [22]. Without fully refining 
requirements prior to the beginning of a project the process of traceability can be difficult and 
traceability between requirements and all stages of development is required by the FDA [23].   
As safety critical software, such as medical device software, can place patients, clinicians 
and third parties at potential risk, medical device software developers must perform adequate 
risk management activities to ensure the software they are developing is safe and reliable. 
Boehm and Turner [19] suggest that risk management activities can be a barrier to adoption  
as agile practices do not provide sufficient guidance as how to perform the necessary risk 
management activities.  
Another perceived barrier to adopting agile practices is that software developed using 
agile practices is of a lower quality than software developed following traditional plan driven 
lifecycles [19]. As medical device software is safety critical it must be developed to the 
highest quality possible. 
Agile methodologies such as XP recommend short releases with continuous feedback [24]. 
When developing medical device software, it is not possible to release incomplete software 
and await feedback as the software must be fully tested and working before it is used in 
patient treatment [25].  
An additional potential barrier to adopting agile practices in the development of both 
safety critical and non-safety critical software is the loss of management control. Agile 
methodologies recommend that development teams are self-organising. This process of self-
organising teams removes some of the decision making powers from management [26]. This 
may result in a loss of management control and for agile practices to succeed organisational 
support is required [27].  
5.   SURVEY OF MEDICAL DEVICE SOFTWARE DEVELOPERS  
In order to gain an understanding of the barriers to the adoption of agile practices we 
performed a questionnaire based survey with medical device software development 
organisations within Ireland. The literature review outlined in section 1 identified the 
perceived barriers to agile adoption and the survey results have been used to determine actual 
barriers to adopting agile practices when developing medical device software. 
Within Ireland there are approximately 160 medical device manufacturers [28]. No 
research has been conducted to date to suggest how many of these organisations develop 
medical device software. As a result when determining sufficient sample size, a decision was 
made to assume all of these organisation develop medical device software. Using sample size 
equations, a sufficient sample size was determined to be twenty organisations. 
 As a result of this, the survey was conducted amongst twenty medical device software 
development organisations in Ireland with multiple responses from each organisation. These 
organisations ranged from small indigenous manufacturers to large multinational 
manufacturers. The devices produced by theses manufacturers range from Class I – Low Risk 
to Class III – High Risk‡ products. The primary goal of this survey was to gain a deeper 
insight into the medical device software development industry to further assist with our on-
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going research. Participants who took part in the survey included all levels of the 
development team and internal stakeholders such as managers and senior management.  
5.1 RESEARCH METHODOLOGY 
When developing the survey a number of areas needed to be considered. Once the objectives 
had been clearly defined, a mechanism to elicit the required information was needed. The 
survey was constructed in accordance with Sapsford [29]. Sapsford provides a number of 
questions which should be asked prior to constructing a survey: 
• What’s the problem? 
• What kind of answer am I looking for? 
• What kind of an argument might lead from the question to the answer? 
• What kind of evidence will I need to sustain this kind of argument? 
[29, p.13]. 
Based upon these questions the survey was constructed. Based upon this method suggested 
by Sapsford and by Frink [30] a bottom up approach for question formulation was used. Both 
Sapsford and Frink advocate looking at which information you want to receive from the 
survey and developing the survey questions accordingly. The process of developing the 
survey questions was an iterative one. The iterative lifecycle of the question formulation is 
shown in the figure 1. 
 
 
Figure 1 shows the transition from the data required from the question through to being 
entered into the survey. This process was completed for each question in the survey. The 
benefit to this method of question construction is that each question has been validated before 
being entered into the survey. Once the survey was completed it was distributed via web link. 
6.   RESULTS OF THE SURVEY 
The first piece of key information obtained by the survey was which software development 
lifecycle the organisations are following. As part of this on-going research, recommendations 
will be made as to how adopting agile practices can resolve problems associated with the 
current lifecycle being followed.  
Following on from this question, participants were provided with a list of activities that are 
required to be completed in the development of safety critical software. Participants were 
requested to rate how much importance they place on each of these activities and to rate how 
effective they deem their organisation to be at performing these activities. The objective of 
this question was to understand which areas of safety critical software development are being 
performed most effectively. Again as part of this on-going research, information is being 
collected that will identify which stages of development pose the most difficulty to medical 
device software developers. This information will eventually be used to help answer research 
questions 1 and 2.  
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Figure 1 Iterative Process of Question Formulation 
Finally participants were asked a series of questions relating to agile software 
development. Participants were provided with a list of 10 potential barriers to agile adoption 
when developing medical device software. The goal of this question was to evaluate the 
findings of the literature review. Participants where then asked what the actual barriers were 
within their own organisation to the adoption of agile methods. This question was used to 
establish what these barriers are and if commonality could be identified across organisations 
as to what actual barriers exist in relation to agile adoption. A barrier being defined as an 
actual barrier does not imply that the barrier is insurmountable. To maximise the amount of 
relevant information gathered, space was provided for the respondents to add additional 
information and/or comments for each question as they deemed necessary. 
The survey identified that 50% of the organisations are developing software in accordance 
with the V-Model.  An important finding was that another 25% of the organisations are 
developing medical device software in accordance with agile practices. The remaining 25% 
of organizations are developing software in accordance with other development lifecycles 
such as the Waterfall model.  As part of the survey, respondents were asked what they believe 
to be the barriers to agile adoption. The survey revealed that 25% of respondents reported 
“Lack of Documentation” as a barrier to agile adoption.  In addition 25% of respondents 
reported “Regulatory Compliance”, whilst 16% of respondents reported “Lack of Up-Front 
planning” and 17% of respondents reported “Insufficient coverage of risk management 
activities” as barriers to agile adoption. These results were consistent with the findings from 
the literature review. 
Finally, respondents of the survey were asked what the actual barriers to adopting agile 
practices are within their organisation.  Of the respondents 50% reported “Lack of 
Experience”, 33% reported that “having to change the existing lifecycle as a barrier to agile 
adoption”, 16% reported “Management Opposed to Change “and 16% reported team size as a 
barrier to agile adoption. A further 17% reported that getting stakeholder buy in as a barrier 
and 17% reported the level of retraining required as another barrier to agile adoption.  
7.   COMPARISON BETWEEN PERCEIVED AND ACTUAL BARRIERS 
Table 1 presents a list of the perceived barriers based on our literature review and the actual 
barriers to agile adoption when developing medical device software based on our survey 
results. It can be seen in table 1 that a number of the perceived barriers are also actual barriers 
to using agile practices when developing medical device software. An important point to 
emerge from our research is how requirements can be identified and successfully managed in 
the context of utilising agile practises. Regulatory bodies require medical device software 
developers to document requirements prior to development. These requirements are then used 
during the development stages to provide traceability. Agile principles dictate that 
requirements must be fluid throughout a development project and this can be seen as a barrier 
as we have outlined in section 4.  
However, regulatory bodies do recognise the acceptability of what can be termed an agile 
approach to requirements. The FDA GPSV states [9]:  
“Most software development models will be iterative. This is likely to result in several 
versions of both the software requirement specification and the software design 
specification. All approved versions should be archived and controlled in accordance 
with established configuration management procedures”.  
Table 1 Perceived and Actual Barriers to Agile adoption 
Perceived Barriers Actual Barriers 
• Regulatory Control • Regulatory Control 
• In-sufficient coverage of Risk 
Management Activities 
• Requirements Management 
• In-sufficient coverage of Risk 
Management Activities 
• Lack of  up-front planning 
• Traceability issues • Lack of documentation 
• Loss of management control • Management opposed to change 
• Lower quality software • Team size 
 • Modification of existing lifecycle 
 • Lack of Experience using agile 
• Getting Stakeholder Buy In 
• Level of Retraining Required 
This emerged from our detailed analysis of the relevant regulations, standards and guidance 
documents. This was not evident from the published academic literature in this area, in fact 
the opposite was the case as we have stated.  
This provides an example of how the perceived barriers to agile adoption can be 
overcome. Further research will be undertaken to evaluate and determine how each of the 
other barriers identified can be addressed by employing specific agile practices or by 
integrating agile practices with a plan driven lifecycle. 
8.   CONCLUSIONS 
Medical device software must be developed in accordance with the appropriate regulatory 
requirements and development standards of the region into which it is being marketed. For 
the US, these regulations are dictated by the FDA. They recommend medical device 
development organisations follow IEC 62304 when developing regulatory complaint 
software. Neither the regulations or standards dictate which SDLC should be followed then 
developing regulatory compliant software; however medical device software is typically 
developed in accordance with the V-Model. The V-Model suffers the same problems as with 
all sequential plan driven SDLC such as a large emphasis being placed on up-front 
requirements and the difficulty accommodating a change once development has begun. To 
overcome these challenges, this research is exploring the possibility of adopting agile 
practices when developing medical device software in conjunction with a plan driven 
software development lifecycle.  
 To understand whether it was feasible to adopt agile practices a literature review of 
development standards and regulations was performed. This literature review revealed there 
to be no direct barriers by regulatory bodies or development standards to adopting agile 
methods when developing medical device software. To validate the findings of this literature 
review, a questionnaire based survey was performed with medical device development 
organisations. This survey revealed two types of barriers, perceived and actual. Perceived 
barriers are barriers which organisations feel exist, but through the literature review 
performed are in fact only superficial. Actual barriers are barriers which exist which directly 
prevent the adoption of agile methods when developing medical device software. Examples 
of perceived barriers include: Regulatory Control; Traceability Issues and Lower Quality 
Software. Examples of the actual barriers include: Lack of Stakeholder Buy-In, Lack of 
Experience using agile and the level of retraining required. The literature review, 
questionnaire based survey and AAMI TIR 45:2012 act as evidence that there are no external 
barriers to adopting agile methods when developing medical device software and that barriers 
that do exist, are primarily in-house barriers within the organisation which can be overcome. 
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